2020
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansMaleMelanomaMiddle AgedNeoplasm MetastasisSkin NeoplasmsSurvival AnalysisUveal NeoplasmsConceptsCheckpoint inhibitorsOverall survivalMetastatic melanomaPrimary tumorLocal therapyCutaneous melanomaAnti-PD-1 antibodyAggressive multidisciplinary approachCutaneous primary tumorPrimary tumor histologyMedian overall survivalSingle institutional experienceRare melanoma subtypeMedian OSMetastatic diseaseProgressive diseaseAcral skinComplete responsePD-1PD-L1Uveal tractTumor histologyCombination therapyCTLA-4Longer survival
2014
A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors
Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH. A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. Annals Of Surgery 2014, 259: 204-212. PMID: 23673766, PMCID: PMC4048026, DOI: 10.1097/sla.0b013e31828f3174.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsStaging systemSimple prognostic toolNeuroendocrine tumorsPrognostic toolStage IFive-year overall survival rateNonfunctional pancreatic neuroendocrine tumorsMain staging systemsAJCC stage ITumor staging systemOverall survival rateAmerican Joint CommitteeSingle-institution seriesKi-67 labelingPrognostic factorsSurvival prognosticationSingle institutionJoint CommitteeMultivariate analysisNatural historyComparison of reportsPatientsNeoplasmsSurvival
2011
Tumor-Associated Antigen Expressing Listeria monocytogenes Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases
Olino K, Wada S, Edil BH, Pan X, Meckel K, Weber W, Slansky J, Tamada K, Lauer P, Brockstedt D, Pardoll D, Schulick R, Yoshimura K. Tumor-Associated Antigen Expressing Listeria monocytogenes Induces Effective Primary and Memory T-Cell Responses Against Hepatic Colorectal Cancer Metastases. Annals Of Surgical Oncology 2011, 19: 597-607. PMID: 21979110, PMCID: PMC4498288, DOI: 10.1245/s10434-011-2037-0.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAnimalsAntigens, DifferentiationAntigens, NeoplasmAntineoplastic Agents, AlkylatingCarcinomaCD8-Positive T-LymphocytesCell Line, TumorColonic NeoplasmsCTLA-4 AntigenCyclophosphamideFemaleImmunotherapyInterferon-gammaListeria monocytogenesLiver NeoplasmsLymphocyte CountMiceMice, Inbred BALB CProgrammed Cell Death 1 ReceptorStatistics, NonparametricSurvival AnalysisT-Lymphocytes, RegulatoryConceptsT cell responsesEffector memory T cellsMetastatic colorectal cancerMemory T cellsTumor rechallengeColorectal cancerT cellsTumor-specific T-cell responsesAntigen-specific effector CD8Tumor-specific cytotoxic CD8Antitumor T-cell responsesEffective antitumor T-cell responsesMemory T cell responsesHepatic colorectal cancer metastasesCurrent immunotherapeutic strategiesImmune checkpoint moleculesColorectal cancer metastasisCTLA-4 expressionTumor-associated antigensTumor associated antigensCT26 colon cancer cell lineL. monocytogenes strainsColon cancer cell linesImmunologic milieuCancer cell lines